Polyrizon completes manufacturing upscaling milestone for nasal spray platform

Polyrizon (PLRZ) announced the completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform. During the upscaling process, Polyrizon and its manufacturing partner transitioned from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to validate key parameters of PL-14 formulation. The milestone demonstrates that the PL-14 formulation can be reliably produced at increased batch volumes while maintaining high-quality specifications. The manufacturing process is set to support the clinical trial material needed for Polyrizon’s clinical trial, which is expected to commence in 2026, offering high-quality and compliant production in line with USA and European regulatory standards.